InVivoMAb recombinant Flt-3L-Ig (hum/hum)

Catalog #BE0342
Product Citations:
Flt-3L Fc-G1
Mouse, Human

$448.00 - $11,682.00

Choose an Option...
  • 100 mg - $11,682.00
  • 50 mg - $8,265.00
  • 25 mg - $5,492.00
  • 5 mg - $1,638.00
  • 1 mg - $448.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Details

Flt-3L (FMS-related Tyrosine Kinase 3 Ligand) is an endogenous protein that functions as a cytokine and growth factor. Flt-3L is crucial for the development of conventional dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs). Recombinant Flt-3L-Ig is a fusion protein consisting of human Flt-3L fused to the Fc portion of human IgG1. This fusion protein is useful for activating Flt3 signaling and inducing the expansion of DC populations. Human Flt-3L-Ig is frequently reported to stimulate Flt3 signaling in vivo in mice.


Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Conjugation This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin <2EU/mg (<0.002EU/μg)
Determined by LAL gel clotting assay
Purity >95%
Determined by SDS-PAGE
Sterility 0.2 μM filtered
Production Purified from cell culture supernatant in an animal-free facility
Purification Protein A
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
    • Cancer Research
    • ,
    Deciphering the immunopeptidome in vivo reveals new tumour antigens.

    In Nature on 1 July 2022 by Jaeger, A. M., Stopfer, L. E., et al.


    Immunosurveillance of cancer requires the presentation of peptide antigens on major histocompatibility complex class I (MHC-I) molecules1-5. Current approaches to profiling of MHC-I-associated peptides, collectively known as the immunopeptidome, are limited to in vitro investigation or bulk tumour lysates, which limits our understanding of cancer-specific patterns of antigen presentation in vivo6. To overcome these limitations, we engineered an inducible affinity tag into the mouse MHC-I gene (H2-K1) and targeted this allele to the KrasLSL-G12D/+Trp53fl/fl mouse model (KP/KbStrep)7. This approach enabled us to precisely isolate MHC-I peptides from autochthonous pancreatic ductal adenocarcinoma and from lung adenocarcinoma (LUAD) in vivo. In addition, we profiled the LUAD immunopeptidome from the alveolar type 2 cell of origin up to late-stage disease. Differential peptide presentation in LUAD was not predictable by mRNA expression or translation efficiency and is probably driven by post-translational mechanisms. Vaccination with peptides presented by LUAD in vivo induced CD8+ T cell responses in naive mice and tumour-bearing mice. Many peptides specific to LUAD, including immunogenic peptides, exhibited minimal expression of the cognate mRNA, which prompts the reconsideration of antigen prediction pipelines that triage peptides according to transcript abundance8. Beyond cancer, the KbStrep allele is compatible with other Cre-driver lines to explore antigen presentation in vivo in the pursuit of understanding basic immunology, infectious disease and autoimmunity. © 2022. The Author(s), under exclusive licence to Springer Nature Limited.